The effect of the JAK2 V617F mutation on PRV-1 expression
, an acquired mutation of JAK2, is present in a majority of patients with polycythemia vera and to a lesser extent among patients with the other myeloproliferative disorders. We analyzed the effect of JAK2 V617F on the expression of polycythemia rubra vera 1(PRV-1), using an in vitro model. Compared to wild-type JAK2, the presence of JAK2 V617F increased both PRV-1 protein and mRNA levels in murine myeloid cells. A JAK2 inhibitor eliminated the V617F-induced increase in PRV-1 expression. 
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, a gain-of-function mutation in the pseudokinase domain of JAK2, has been detected in more than 80% of patient with polycythemia vera, in less than half of patients with essential thrombocythemia or agnogenic myeloid metaplasia, and infrequently in patients with atypical myeloproliferative disorders (MPD).
1-5 JAK2 V617F is not the only molecular change detected with a higher frequency in MPD patients. High expression of PRV-1 has also been frequently found among patients with polycythemia vera 6 and was correlated with the presence of endogenous erythroid colonies in patients and with growth-factor-independent proliferation of heterologous cells. 7 There are several reports on the co-existence of JAK2 V617F and high expression of PRV-1 in patients with polycythemia vera. [8] [9] [10] We studied the causal relationship between JAK2
V617F and overexpression of PRV-1 in murine myeloid cells. We used FDCP-EpoR cells transduced with MSCV-GFP retroviral vector carrying either wild-type or mutant JAK2 cDNA or the empty vector.
2 These cell lines were kindly provided by Dr. William Vainchenker (INSERM U362, Institut Gustave Roussy, Paris XI University, France). Cells were kept in RPMI medium enriched with 10% fetal calf serum and supplemented with 10 ng/mL of interleukin-3 (Sigma Aldrich). The cell fluorescence caused by the green fluorescent protein (GFP) was used as a surrogate marker for detecting the level of expression of JAK2. The surface level of PRV-1 was measured by flow cytometry using anti CD177 antibody (MEM166, BD Pharmingen) and a phycoerythrinconjugated rabbit anti mouse secondary antibody (Zymed). After 1 hour of incubation at room temperature and subsequent washes, cells were analyzed by twocolor flow cytometry, to detect PRV-1 and GFP simulta- WT increased the expression of native PRV-1 on FDCP cells ( Figure 1A and 1B) . Additionally, we studied the effect of the JAK2 mutation on the mRNA level of PRV-1 using a real-time reverse transcription polymerase chain reaction (RT-PCR). We designed oligonucleotides and a FAM-conjugated probe according to the sequence of the murine PRV-1 gene. The murine PRV-1 gene sequence and its intron-exon boundaries were determined by using the reported murine PRV-1 mRNA (NM_026862) and the NCBI Map Viewer website. Total RNA was extracted from the transduced FDCP cells, reverse transcribed to double-stranded DNA using a cell to cDNA kit (Ambion), and used as a template in the realtime PCR. We used the 18S RNA as an internal standard and normalized all the real-time PCR results to that of the FDCP-Sham cells. FDCP-JAK2 V617F cells had significantly higher amounts of PRV-1 mRNA than had FDCP-JAK2 WT cells ( Figure 1C; ∆∆Ct±s.e. of -9.8±0.3 and -1.7±0.8, respectively; n=9, p=0.0006). To investigate whether the JAK2 mutation is the cause of PRV-1 overexpression, we studied the effect of a JAK2-specific tyrosine kinase inhibitor on PRV-1 expression. This inhibitor WT cells. Our results show that mutation in JAK2 could be responsible for an increase in the PRV-1 expression in MPD. One intriguing question is whether PRV-1 overexpression is only a phenotypic change or whether it has any functional consequence. We have previously shown that overexpression of PRV-1 in a heterologous cell line can promote proliferation in the absence of growth factors.
7 Considering our observations, we put forward the following hypothesis: in MPD, JAK2
V671F is the cause of PRV-1 overexpression and the latter increases cell proliferation. This hypothesis should be tested by studying the effect of selective inhibition of PRV-1 (in the presence of JAK2 
